Please assess the completion status of the following clinical trial:

Trial Title: Standard Versus High Dose Inactivated Influenza Vaccine in RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of seropositive RA (rheumatoid factor (RF) and/or anti-CCP antibody positive) based on the 2010 ACR-EULAR criteria.~2. At least 6 months of treatment including anti-TNF agents, abatacept, rituximab (dose received within the previous 6 months) and/or methotrexate.~3. Informed consent form signed and dated.~4. Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~1. Vaccination against influenza in the 6 months preceding the trial vaccination.~2. Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or a history of a life-threatening reaction to TIV or to a vaccine containing any of the same substances.~3. History of Guillain-Barré syndrome within six weeks of a previous influenza vaccination.~4. Dementia or any other cognitive condition that could interfere with the trial procedures.~5. Thrombocytopenia or bleeding disorder contraindicating IM vaccination (according to treating rheumatologist).~6. Current alcohol abuse or drug addiction.~7. Moderate or severe acute illness with or without fever. If this exists, vaccination will be deferred until the individual has been medically stable and/or afebrile for at least 24 hours.~8. Signs and symptoms of an acute infectious respiratory illness. If this exists, vaccination will be deferred until the symptoms resolve.~9. Pregnant women (the rationale for excluding this group is not their lack of indication for vaccination but the changes of maternal immune responses during pregnancy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose influenza vaccine (Type: ACTIVE_COMPARATOR): Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
- High dose influenza vaccine (Type: ACTIVE_COMPARATOR): Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)

Based on this trial design, predict the completion outcome and termination type (if applicable).